CAP Partners’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
CAP Partners's CRSP Position: Q3 2026 in Review
CAP Partners increased its CRISPR Therapeutics (CRSP) stake by 7.3% in Q3 2026, buying an estimated $20.5K and bringing the position to 5,596 shares worth $310K. The position accounts for 0.14% of the portfolio, ranked #124.
CAP Partners first reported a position in CRSP in Q1 2026 and has held it in 3 quarters since. 413 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- CAP Partners held 5,596 shares of CRISPR Therapeutics worth $310K as of Q3 2026.
- CAP Partners bought 380 CRISPR Therapeutics shares in Q3 2026, an estimated $20.5K.
- CRISPR Therapeutics made up 0.14% of CAP Partners's portfolio in Q3 2026, its #124 holding.
- CAP Partners first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 413 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on CAP Partners's 13F filing for Q3 2026, filed 19 Oct 2026.